TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01599572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: zinc supplementation
Description: 30mg/day of zinc in the form of zinc gluconate
Study: NCT01463124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lookin' Good Feelin' Good
Description: Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information attention-control
Description: Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
Study: NCT04279652

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined exercise
Description: Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined exercise
Description: Combined exercise program consists of 5 min warm-up exercises, 20 min aerobic exercise, 20 min balance-coordination exercises, 10 min strengthening exercises and 5 min cooling exercises.
Study: NCT00646750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)
Description: Day -21: rituximab. 250 mg/m2 iv~Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).~Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1.
Study: NCT02380482

Intervention type: OTHER
Group type: OTHER
Intervention: Transthoracic echocardiography on TBI patients
Description: Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma

Intervention type: OTHER
Group type: OTHER
Intervention: Transthoracic echocardiography on control patients
Description: Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
Study: NCT03396640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unicondylar Knee Arthroplasty
Description: Incision will be midline incision, as with a TKA, for maximum security of blinding.~Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Arthroplasty
Description: Incision will be midline incision, as standard. Standard operative technique will hereafter be used, with minor individual preferences for each surgeon as to whether tourniquet/not, drain or not.
Study: NCT00262639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil and Gabapentin
Description: 2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flumazenil and Gabapentin
Description: 2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
Study: NCT02043587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 IV once daily on days 1 \& 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C \& 2A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
Study: NCT01709253

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam therapy
Description: hypofractionation study using proton beam therapy for prostate adenocarcinoma

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam therapy
Description: hypofractionation study using proton beam therapy for prostate adenocarcinoma

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam therapy
Description: hypofractionation study using proton beam therapy for prostate adenocarcinoma

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam therapy
Description: hypofractionation study using proton beam therapy for prostate adenocarcinoma
Study: NCT02299115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Corticosteroid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigabatrin
Description: Antiepileptic
Study: NCT04439695

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose
Description: Low dose of KBP-V001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intermediate dose
Description: Intermediate dose of KBP-V001

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose
Description: High dose of KBP-V001

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Buffered Saline Solution
Study: NCT02832180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC containing EE and NET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OC containing EE and NET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986142
Study: NCT01062867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG25435
Description: Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
Study: NCT02879734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prophylactic laparoscopic omentopexy
Description: Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
Study: NCT02566356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Nasal Spray
Description: 40 IU of the saline nasal spray will be administered once at the beginning of the visit.
Study: NCT03636412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ambulation
Description: An ambulator will walk with a patient three times a day, based on physical therapy recommendations.
Study: NCT02552212

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Certolizumab Pegol
Description: * Active Substance: Certolizumab Pegol~* Pharmaceutical Form: Prefilled syringe~* Concentration: 200 mg / ml~* Route of Administration: Subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Active Substance: Placebo~* Pharmaceutical Form: Prefilled syringe~* Concentration: 0.9 % saline~* Route of Administration: Subcutaneous injection
Study: NCT00370812

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amniotic membrane transplantation
Description: AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: amniotic membrane transplantation
Description: AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
Study: NCT03626883

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single-bundle, single-hamstring ACL reconstruction
Description: anterior cruciate ligament reconstruction with single hamstring tendon

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single-bundle, double-hamstring ACL reconstruction
Description: anterior cruciate ligament reconstruction with 2 hamstring tendons
Study: NCT00262639

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
Study: NCT03358004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine Tartrate
Description: Metronomic treatment with vinorelbine 50 mg (three times/week) until progression in ARM A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine 500 MG
Description: Metronomic treatment with capecitabine 500 mg (three times/day) combined with vinorelbine 40 mg (three times/week) with until progression
Study: NCT04494880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Injection
Description: Treatment group receives Marcaine (Bupivacaine) injected into one breast following breast reduction surgery and a saline injection in the other group.
Study: NCT00683631

Intervention type: OTHER
Intervention: TheraSphere HUD
Description: TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
Study: NCT03667209

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education (PNE) and traditional exercise
Description: PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain neuroscience education (PNE) and suspension exercise
Description: PNE will cover the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience.~Exercise of the neck and scapular regions, including strength, motor control and stretching exercises. delivered in suspension.~Initially (first 3 sessions) will be delivered individually and then (last 3 sessions)in small groups (4 participants). A total of 6 sessions will be delivered during 6 weeks. Each session will take around 1 hour.
Study: NCT06317090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regeneration
Description: a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guided bone regeneration
Description: a non-resorbable membrane was used as a space maintainer, filled with a particulated bone graft.
Study: NCT04005365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: add propranolol in gastric cancer patients who need to receive preoperate chemotherapy
Study: NCT04461158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator Services
Description: The navigator services most commonly provided include facilitation and coordination of care, practical support, including transportation and financial assistance, appointment scheduling and reminders, education and psychosocial support
Study: NCT03122197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Oral Tablet
Description: Administration: Letrozole will be given orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Oral Tablet
Description: Administration: Letrozole will be given orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole Oral Tablet
Description: Administration: Letrozole will be given orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 50 mg/m2 TMZ administered orally once daily
Study: NCT00565357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silicone Earplugs
Description: Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control
Description: Standard care in the neonatal intensive care unit
Study: NCT01750840

Intervention type: DEVICE
Intervention: Biomet® EBI Bone Healing System
Description: A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.

Intervention type: DEVICE
Intervention: Biomet Orthopak® Non-Invasive Bone Growth Stimulator System
Description: A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.

Intervention type: DEVICE
Intervention: Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator
Description: A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
Study: NCT02737176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco cessation intervention
Description: The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.~During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.~Even if the subjects failed to abstain from smoking, the treatment is continued.~In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy.
Study: NCT01224106

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gantenerumab
Description: Participants received Gantenerumab at 105 mg , 225 mg, or at doses up to 1200 mg SC injection Q4W.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo SC injection Q4W.
Study: NCT03320486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapaconazole
Description: Application of 1 to 3 grams, depending on the lesion extension, per affected foot.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketoconazole
Description: Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
Study: NCT01174589

Intervention type: OTHER
Group type: OTHER
Intervention: Strength training
Description: to compare if there is a difference between 6 or 12 weeks of physical strength training

Intervention type: OTHER
Group type: OTHER
Intervention: Strength training
Description: to compare if there is a difference between 6 or 12 weeks of physical strength training
Study: NCT03702140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide, Forteo® or Teribon
Description: To examine the effects of terimaratide less than 6 months in osteoporosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide, Forteo® or Teribon
Description: To examine the effects of terimaratide less than 6 months in osteoporosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide, Forteo® or Teribon
Description: To examine the effects of terimaratide less than 6 months in osteoporosis
Study: NCT04165304

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: sugar reduction
Description: sugar reduction in the offered drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: sugar reduction
Description: sugar reduction in the offered drinks
Study: NCT02666040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ULTRAPRO® meshes
Description: The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prolene® meshes
Description: The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Detecting the mode of admission to hospital
Description: Ordinary admission or day surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Detecting the mode of admission to hospital
Description: Ordinary admission or day surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duration of surgery
Description: Time operating room
Study: NCT03309306

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Natural Environment/Reduce Food Waste
Description: Participants will use the FoodImage app to capture data on food purchases, food waste that occurs during food preparation, food waste that is present after eating, and food waste from food purges in free-living conditions. Participants will use the app to record food waste for approximately 4-7 days over the subsequent week. They will also be provided with the following:~1. Feedback on the amount of food waste their household created during the first week,~2. A goal to reduce the next week's food waste by 20% or more, and~3. Tips on how to reduce household food waste adapted from current consumer campaigns
Study: NCT03328078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib will be provided as a tablet dosage form to be taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib will be provided as a tablet dosage form to be taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib will be provided as a tablet dosage form to be taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emavusertib
Description: Emavusertib will be provided as a tablet dosage form to be taken BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be provided as a tablet or capsule dosage form to be taken QD.
Study: NCT02666040

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Duration of surgery
Description: Time operating room

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia volume and type used
Description: Anesthesias used: infiltration, followed by spinal, general, epidural.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anesthesia volume and type used
Description: Anesthesias used: infiltration, followed by spinal, general, epidural.
Study: NCT05263687

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Maximal exercise test
Description: Each participants will conduct a spirometry test and exercise test on treadmill (using Modified Bruce Protocol) or cycle ergometer. Quark CPET metabolic cart (Cosmed, Rome, Italy) will be used to collect and analysis gas exchange, ECG, gas volume in addition rating of perceived exertion will be asked.
Study: NCT04803019

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: DEB-TACE
Description: The chemotherapy used in this arm is the Doxorubicin that will be carried into the tumor by Embozene TANDEM® (Boston Scientific) microspheres. TANDEM® embozene microspheres are made of non-resorbable, biocompatible, hydrogel microspheres, subjected to precision calibration and coated with an inorganic perfluorate polymer (Polyzene®-F).~TANDEM® embozene microspheres are available in three different sizes, in 2 ml and 3 ml volumes of product and are supplied in preloaded vials and syringes.The maximum loadable amount on the hydrospheres 50 mg of Doxorubicina for ml. The maximum injectable dose of Doxorubicin for each treatment is 150 mg and therefore the maximum amount of microspheres that can be used for each treatment is 3 ml. The size of microspheres that will be used in this study is up to 100 ± 25 μm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAE
Description: The TAE will be performed with Embozene microspheres (Boston Scientific). Embozene microspheres are spherical particles of hydrogel, precisely calibrated, biocompatible, non-absorbable and coated with a perfluorinated inorganic polymer (Polyzene®-F). This medical device is available in various sizes; in this study, to avoid that the particle size exceeds the one used for the treatment of arm A, it will be possible to use microspheres with dimensions up to 100 μm (range 75 ± 125 μm).~Embozene microspheres are offered in vials containing 1 ml of suspended product in physiological saline solution for apyrogenic sterile transport. The total volume of the Embozene microspheres, including the transport solution, is about 7 ml. To this product it is necessary to add an appropriate amount of non-ionic contrast medium in order to obtain a homogeneous suspension and with good visibility during the injection under fluoroscopy.
Study: NCT03597503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPN-810
Description: Flexible dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02976545

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI (functional Magnetic Resonance Imaging)
Description: fMRI examination

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI (functional Magnetic Resonance Imaging)
Description: fMRI examination

Intervention type: DEVICE
Group type: OTHER
Intervention: fMRI (functional Magnetic Resonance Imaging)
Description: fMRI examination

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychiatric evaluation
Description: psychiatric evaluation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychiatric evaluation
Description: psychiatric evaluation

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: psychiatric evaluation
Description: psychiatric evaluation
Study: NCT01319513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whey protein bolus
Description: single dose of 25 g whey protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whey protein pulses
Description: 10 2.5 g pulses of whey protein